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ation of RDT and clinical evidence of CTS was 8 years (range, 4
to 12 years). CTS was bilateral in nine patients. It was never
observed in arms or legs untouched by vascular access proce-
dures. Temporary relief of symptoms (pain and/or paresthesias)
was observed after local corticosteroids infiltration. This relief,
together with nerve conduction velocity studies, permits the dif-
ferentiation of CTS from vascular steal syndrome and from acr-
oparesthesias and shoulder pain of osteoarticular origin. The car-
pal tunnel was surgically decompressed in 11 patients. Complete
recovery was obtained in all but one, suffering from synovial am-
yloidosis. In conclusion, with the increasing number of patients
on maintenance hemodialysis for more than 4 years, diagnosis of
CTS should be considered in any dialysis patient suffering from
hitherto unexplained pain in the upper limbs. In our experience,
vascular access procedures always preceded development of the
syndrome.
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Effects of thromboxane synthetase inhibition and thromboxane
B2 administration on glomerular function in the rat. C. Baylis.
Department of Physiology, Manchester University, Manchester,
England. The normal rat kidney possesses the enzymes neces-
sary to synthesize the potent vasoconstrictor and proplatelet ag-
gregating agent thromboxane A2 (TXA2), and its stable and less
potent metabolite thromboxane B2 (TXB2). It is not at present
known, however, whether thromboxane (TX) synthesis is acti-
vated in the normal kidney, or what effect TX has on renal func-
tion in vivo. The following experiments were performed to inves-
tigate these questions. Micropuncture experiments were carried
out on 7 adult male Munich-Wistar rats (a strain that possesses
glomeruli on the kidney surface) in control conditions and again
during i.v. infusion of imidazole (0.05 mmoles/kglmin). In vitro
studies have indicated that imidazole is a potent TX-synthetase
inhibitor. No significant change was seen in single nephron (SN)
GFR or in single glomerular plasma flow rate (QA) with imida-
zole. Protein concentration (C) in afferent glomerular blood (CA)
fell slightly, but efferent glomerular protein concentration (CE)
was not significantly affected by the drug. The mean hydrostatic
pressure difference across the glomerular capillary wall, P, rose
markedly from 35 2 to 45 1 mm Hg (P <0.25, paired t test),
due largely to increased glomerular capillary hydrostatic pres-
sure (P0). In control conditions, rats were at filtration pressure
equilibrium (i.e. P oncotic pressure of efferent glomerular
blood, HE), and only minimum values of the glomerular capillary
ultrafiltration coefficient (K2) could be calculated. Filtration pres-
sure disequilibrium (P > HE) obtained during imidazole in-
fusion and exact values of K2 could be calculated. K2, the product
of glomerular water permeability and available filtration surface
area, averaged a minimum of 0.105 0.01 nll(secmm Hg) in
control conditions and fell significantly to 0.057 0.005 nI/
(secmm Hg) during imidazole infusion (P <0.005). Mean femo-
ral arterial blood pressure (AP) also rose significantly with imida-
zole from 113 4 to 131 4mm Hg (P <0.001). Inhibition of a
potent vasoconstrictor system would be expected to increase QA
and SNGFR; thus, the lack of change in these variables during
TX-synthetase inhibition with imidazole may suggest that little
or no TX is synthesized under normal conditions in the rat kid-
ney. A selective inhibitor of vasoconstrictor TX would however
reduce, rather than raise AP, and since increases in blood pres-
sure were seen with imidazole it seems likely that this drug ex-
erts additional actions in vivo. Similar experiments were carried
out on 6 additional rats in which TXB2 (100 jg/kg/min) was in-
fused into the aorta above the left renal artery. A significant fall
was seen in SNGFR with TXB2 (from 34.7 4.7 to 26.4 4.2 nl/
mm, P <0.005) and QA also declined (from 111.6 16.1 to 91.2
12.6 nI/mm, P = 0.05, N = 5). A small but significant increase
occurred in CA (from 5.7 0.2 to 6.2 0.2 g/dl, P <0.005) while
CE did not change. The value of AP was unaffected by TXB2, and
although a slight increase in AP was seen, this was not statistical-
ly significant. Rats remained at filtration pressure equilibrium
during TXB2 infusion, and thus exact values of K2 could not be
calculated. The decline in SNGFR seen during TXB2 infusion
was due both to falls in QA and increases in CA, the latter increas-
ing the oncotic opposition to the ultrafiltration process. Thus, it
seems that TXB2 exerts mild renal vasoconstrictor effects at the
large doses that were administered in these experiments.
Role of the major histocompatibility system in idiopathic mem-
branous nephropathy: Prediction of outcome and response to
treatment. S. A. Cairns, P. Klouda, P. A. Dyer, J. Manos, N. P.
Mallick, and R. Harris. Department of Renal Medicine, Man-
chester Royal Infirmary, and Department of Medical Genetics,
St. Mary's Hospital, Manchester, England. We have demon-
strated a relationship between idiopathic membranous nephropa-
thy (IMN), the major histocompatibility system (MHS) antigen
HLA-DRW3, and complement factor B allotype BfFl. Like the
MHS, factor B is coded on chromosome 6, and, in our series
delta values suggest that BfFI, DRW3, and B18 exist as a hap-
lotype. The clinical course of 40 patients with IMN, followed for
between 2 and 23 years, has been studied in relation to immuno-
genetic markers (Table). The clinical presentation was similar in
the three groups and there was no difference in incidence of fa-
milial renal disease or immunochemical abnormalities. Patients
in group I had a worse prognosis than those in groups II and III;
none remitted, while over 50% of those in groups II and III did (P
= 0.009, Fisher's exact test). Interestingly, one third of those
remitting subsequently relapsed. Decline in renal function oc-
curred in 71% of group! patients but occurred less frequently in
groups 11(22%) and III (33%) (P 0.026).
Group No. of patients B18 BfFI DRW-3
II 22
III 7
7 + + +
+ +
1 — + +
2 + — —
Eighteen of the patients received steroids. Improvement in renal
function and/or decline in proteinuria occurred in 6, 5 of whom
were in group II (DRW3 positive, BfFl negative). None of 3 pa-
tients treated in group I responded. IMN is immunogenetically
heterogeneous, and immunogenetic markers may prove valuable
in determining disease outcome. The suggestion from our data
that patients responsive to treatment may be identified by MHS
I
+
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antigens may be relevant to the use of steroids and immuno-
suppressive drugs in this condition, a subject of considerable de-
bate at present.
1gM-associated mesangial proliferative glomerulonephritis. W.
Law/er, G. Williams, E. J. Acheson, and N. P. Ma/lick. Depart-
ments of Pathology and Renal Medicine, Manchester University
and Manchester Royal Infirmary, Manchester, England. Of 197
consecutive successful nontransplant renal biopsies, 23 were
designated 1gM-associated primary diffuse mesangial prolifera-
tive glomerulonephritis. 1gM was the sole localizing host immu-
noglobulin in 18, and the predominant globulin in 5; C3 was also
present in 18. On light microscopy, variable diffuse and global
mesangial proliferation was seen in all cases, with additional fo-
cal global sclerosis in 16, focal segmental sclerosis in 15, and small
capsular crescents in 7. Ultrastructurally, 13 out of 19 showed
occasional intramesangial electron-dense deposits, and in 18
there were irregular, rather ill-defined areas of increased electron
density in mesangial regions. Of the 23 patients, 13 were male.
Fourteen presented with the nephrotic syndrome, and 9 had
asymptomatic proteinuria; none had macroscopic haematuria.
The age at onset was between 5 and 53 (mean, 28.9 13.6) years.
During followup (10 months to 17.5 years; median 7.0 years), 4
patients remitted, 4 had stable renal function, continuous pro-
teinuria, and no hypertension, 8 showed stable renal function
and continuous proteinuria but developed hypertension, 3 had
renal function deterioration with hypertension, and 4 progressed
to renal death after 3Ji, 10, 14V4, and 16 years; 3 died from non-
renal causes. It is suggested that this should be considered a dis-
tinct clinicoimmunopathological entity.
Infective endocarditis-associated glomerulonephritis in rabbits.
M. Sindrey, J. Barratt, and P. Naish. Medical Research Labora-
tories, North Staffordshire Medical Centre, Stoke-on-Trent,
England. Animal models of immune complex glomerulonephritis
frequently bear little relationship to human disease. For this rea-
son, we have investigated the model of infective endocarditis-
associated glomerulonephritis in the rabbit. Preimmunization of
animals with Streptococcus viridans, production of sterile vege-
tations by passage of a catheter through the aortic valve, and
subsequent i.v. administration of live streptococci lead to infec-
tive endocarditis and exudative glomerulonephritis. The course
of the disease was found to be characterized by the appearance
of circulating immune complexes, deposition of immunoglobu-
lins and C3 in a granular distribution on the glomerular basement
membrane, and finally proteinuria, glomerular polymorph infil-
tration and hypocomplementemia. Gel filtration of serum
showed the circulating complexes to have mol wt's ranging from
4.106 to 5. 10 daltons, as is seen in the equivalent human disease.
Streptococcal antigen could not be demonstrated in glomeruli,
but antiglobulins were present in glomeruli in the majority of ani-
mals that showed circulating immune complexes and glomerulo-
nephntis. Antiglobulins have been demonstrated in glomeruli in
only some forms of chronic glomerulonephritis in humans; the
findings in our experiments suggest that they may also play an
important role in the production of acute glomerular inflamma-
tion.
Effect of blood transfusion on T-suppressor cells in dialysis pa-
tients. M. D. Smith, J. D. Williams, G. A. Co/es, andJ. R. Sala-
man. K.R. U.F. Institute of Renal Disease, The Royal Infirmary,
Cardiff, Wales. Many reports have confirmed the beneficial ef-
fect of previous blood transfusion on renal allograft survival. The
mechanism whereby transfusions produce this effect is un-
known, although it has been suggested that this is due to an effect
on T-suppressor cells, The present study reports the results of
the T-suppressor cell response to transfusion in dialysis patients.
Fifteen chronic dialysis patients who had not received previous
blood transfusions were studied. Each patient was transfused
with 2 U of packed red blood cells. Blood was obtained from the
patients for suppressor cell studies 1 week before transfusion and
1 week, 3 weeks (15 patients), and 16 weeks (7 patients) after
transfusion. Suppressor cell function (SCF) was measured by the
Concanavalin A enhancement method, and the number of these
cells (SCN) was estimated by a rosetting method utilizing the
ability of the Fe receptors for IgG on T-suppressor cells to
rosette with ox red blood cells sensitized with IgG amborecep-
tor. Before transfusion, 9 patients had normal SCF, and in 6 the
function was low. One week after transfusion, there was a de-
crease in SCF in all of the patients, and at 3 weeks there was a
marked rise in SCF in 13 of 15 patients and a fall in 2. Of the 7
patients studied at 16 weeks, the SCF remained high in 2 of them.
There was no clear observable effect on SCN. The increase in
SCF produced by blood transfusion did not appear until 3 weeks
after transfusion and persisted in 28% of the patients 5 months
after transfusion. If this change in T-suppressor cell function is
responsible for the improved graft survival after transfusion the
timing of blood transfusion with respect to the date of trans-
plantation could be of vital importance. Transplants performed
within 3 weeks of a transfusion would be unlikely to benefit from
the increase in SCF.
Mineralocorticosteroid and glucocorticosteroid requirements for
renal acid excretion by adrenalectomized rats. C. S. Wilcox, D. A.
Cemerikic, and G. Giebisch. Department of Physiology, Yale
Medical School, New Haven, Connecticut, USA. Adrenal-
ectomy impairs renal acid elimination. We investigated whether
a mineralocorticosteroid (given as d-aldosterone) or a glucocorti-
costeroid (given as dexamethasone orthophosphate) could re-
verse this defect. Male rats (N = 105, 15010 200 g body wt) were
adrenalectomized under ether anaesthesia and maintained on 1%
saline to drink; they received a low potassium diet to prevent
hyperkalaemia. Six control rats were sham-operated: they were
maintained on tap water and a standard diet. On days 3 and 6
following surgery, all rats received by gavage an acid and buffer
load of 5 ml/lOO g body wt of a solution containing 187 mmoles/
liter NH4CI, 95 mmoles/liter Na2HPO4 and 18 mmoles/liter
NaH2PO4. Urine was collected under oil for 3 hours, starting 1
hour after gavage, and analyzed for volume, Na, K, total CO2,
titratable acidity (TA: by titration to blood pH) and total am-
monia" (NH4: by back-titration after addition of a neutral for-
maldehyde). Aldosterone was found to exert its maximal renal
action within 6 hours and was given 2 hours before urine collec-
tion. Dexamethasone took longer to develop its full action: thus,
each dose was given twice, 18 hours and 2 hours before urine
collections. Dosages were calculated as g/l00 g body wt and
given i.m. A possible permissive" action was assessed by re-
testing with one drug in the presence of a fixed dose of the other.
Aldosterone (dosages of 0.01, 0.1, 1.0 and 10 g/100 g body wt)
was tested alone and again with dexamethasone (0.2 g/l00 g
body wt). Dexamethasone (dosages of 0.02, 0.2, 2.0, and 20 g/
100 g body wt) was tested alone and again with aldosterone (1.0
j.g/l0O g body wt). There were 6 to 15 rats in each group. No
urine contained a total CO2 above I mmoles/liter. Adrenal-
ectomized rats without coi-ticosteroid replacement, compared
with sham-operated controls, had significantly (P <0.005) higher
values for urinary pH and lower rates of titratable acid (UTAV)
and ammonia (UNH V) excretion. Their urinary Na:K ratio was
increased. Aldosterone (at doses from 0.1 jig/lOO g body wt) fully
reversed the defects in urinary Na:K ratio and pH but did not
alter UNH V. It increased UTAV modestly at the highest dosage.
Dexametfiasone fully corrected the defects in urinary Na: K ratio
and UNH V at doses from 2.0 g/l00 g body wt, and the defect in
UTAV at the highest dose level, but did not significantly alter uri-
nary pH. Supplementation with one drug did not alter the re-
sponses to the other. Thus, adrenalectomy induces widespread
defects in renal acid elimination that require both mineralo-
corticosteroids (for urinary acidification) and glucocorticoste-
roids (for buffer and ammonia excretion) for its correction.
